Author Archives: admin

Human blastocyst-like structures generated entirely from pluripotent stem cells. Shifting the paradigm of developmental biology? – ESHRE

Human blastocyst-like structures generated entirely from pluripotent stem cells. Shifting the paradigm of developmental biology?

Four research groups have in the past few weeks independently reported that they have grown clusters of cells which mimic the function of human blastocysts. Susana Chuva de Sousa Lopes, co-ordinator of ESHREs SIG Stem Cells, and deputy Mina Popovic describe how these breakthroughs might extend the present limits on human embryo research.

Until now knowledge of early mammalian development has relied heavily on observing and manipulating human and animal embryos directly. Nevertheless, the relatively short timeframe available for analysis, coupled with the inaccessibility of research material, has inherently limited our understanding. Fired by their ambitious quest to elucidate the cellular and molecular complexities of human embryos, researchers are currently rethinking the way in which we study early human development in vitro.

Embryo-like structures are taking precedence. Unlike embryos resulting from the process of fertilisation, these structures are formed by stem cell coaxing, providing a novel, scalable platform for interrogating developmental pathways.

Human pluripotent stem cells (hPSCs) have been extremely valuable for understanding aspects of early human development. However, hPSCs have thus far only been successfully applied for capturing early human post-implantation development, recapitulating aspects of epiblast, trophoblast and amniotic cavity formation, and some features of axis development and gastrulation.(1) Traditional culture systems have lacked the complexity to model the spatio-temporal dynamics of a blastocyst.

Now, in a recent breakthrough, two research groups have harnessed the synergy between stem cell and developmental biology to generate the first human blastocyst-like structures, termed blastoids.(2.3) These papers were accompanied by two additional preliminary reports describing similar results.(4,5). Yu et al and Liu et al applied a 3D-microwell system and specific culture media to support the differentiation of hPSC towards structures that resembled human blastocysts in terms of their morphology, size and cell number.

In both studies, ~20% of the cell aggregates formed blastoids after 6-8 days. Detailed gene expression analysis revealed the presence of distinct embryonic lineages; however, the blastoids also contained many unidentified cell types. The authors thus cultured the blastocyst-like structures beyond the implantation stages in vitro. Interestingly, a small portion of outgrowths revealed phenotypes akin to the epiblast and amniotic cavity. Nevertheless, these findings warrant careful interpretation. Ultimately, thorough characterisation remains a challenge, as there are currently no optimal culture systems to mimic human peri-implantation in vitro.

With advances in high resolution genetic analysis and imaging technologies, research using blastoids certainly holds promise. For instance, blastoids may be generated in large numbers, allowing sufficient material for in-depth assays and high-throughput screens. Furthermore, they are more amenable to rapid genetic modifications than in experiments involving (natural) human embryos. However, as Heuser and Streeter elegantly wrote in 1941: The embryo is a machine that needs to function while it is being built.

Accordingly, it is important to appreciate that these models do not capture the full complexity of human blastocysts. Blastoids do not have a zona pellucida and, while some primitive endoderm (PE)-like cells were present, a defined PE cell layer could not be observed. Furthermore, immunofluorescence staining and transcriptomic analysis show inconsistencies for trophectoderm markers, while many of the blastoid cells cannot be correlated to in vivo counterparts. Several further limitations persist, such as poor efficiency and heterogeneity within and between different blastoids. Most importantly, the developmental potential of human blastoids remains to be determined. At present, blastoids generated from mouse PSCs do not have the capacity to develop beyond the early post-implantation stages.

Alongside scientific innovation, harnessing the full potential of human blastoids will also require urgent ethical reflection. While blastoids may overcome the destruction of human embryos, their genome is not individually unique, but rather represents a genetic clone of the stem cells or donor cells of origin. Hence, the legal and ethical implications associated with informed consent for the application of hPSCs will require revision. For instance, a donor may agree to his/her stem cells being used to generate tissues, but not for the creation of cloned embryos.

In addition, evaluating the extent to which the use of blastoids raises ethical concerns typical of human embryo research, such as the 14-day rule, will be crucial. If these structures were to acquire functionality, the definition of an embryo will require careful rethinking. Perhaps in the future, some of the ethical and legal restraints imposed on human embryo research may be overcome in blastoids by ensuring non-viability. For instance, gene editing may be used to introduce a necessary lethal mutation in the donor hPSCs.

In this context, the multidisciplinary approach offered by stem-cell based embryo models does provide a new edge. Depending on their functionality and moral status, blastoids may prove valuable in complementing human blastocysts for research. This integrated approach will be important not only for addressing fundamental biological questions, but perhaps also for improving ART, for studying implantation, modelling specific diseases related to early pregnancy and improving embryo selection. Armed with this potential, we are undoubtedly facing thrilling times ahead in human embryo research.

1. Rossant J, Tam PP. Opportunities and challenges with stem cell-based embryo models. Stem Cell Reports 2021; doi:10.1016/j.stemcr.2021.02.002. 2. Yu L, Wei Y, Duan J, et al. Blastocyst-like structures generated from human pluripotent stem cells. Nature 2021; 591: 620-626. doi:10.1038/s41586-021-03356-y 3. Liu X, Tan JP, Schrder J, et al. Modelling human blastocysts by reprogramming fibroblasts into iBlastoids. Nature 2021; 591: 627-632. doi:10.1038/s41586-021-03372-y 4. Fan Y, Min ZY, Alsolami S, et al. Generation of human blastocyst-like structures from pluripotent stem cells. bioRxiv 2021; preprint at doi:10.1101/2021.03.09.434313 5. Sozen B, Jorgensen V, Zhu M, et al. Reconstructing human early embryogenesis in vitro with pluripotent stem cells. bioRxiv 2021; preprint at doi.org/10.1101/2021.03.12.435175

Continue reading here:
Human blastocyst-like structures generated entirely from pluripotent stem cells. Shifting the paradigm of developmental biology? - ESHRE

New Michigan law requires those receiving Johnson & Johnson vaccine be told it was developed using stem cells | TheHill – The Hill

A new law in Michigan requires residents receiving the Johnson & Johnson COVID-19 vaccine to be informed the shot was developed using a stem cell line originating from an aborted human fetus, according to The Detroit Free Press.

The mandate was part of a state bill passed by the Republican-majority legislature and signed by Michigan Gov. Gretchen Whitmer (D) earlier this month that allocated funds from the federal coronavirus relief package. It requires anyone whos given a vaccine paid for through the $110 million relief legislation to be provided with information or informed if and in what manner the development of the vaccine utilized aborted fetal tissue or human embryonic stem cell derivation lines.

Our country is in a historic fight against the Coronavirus. Add Changing America to your Facebook or Twitter feed to stay on top of the news.

According to the Free Press, the requirement does not state how the notification process would work, who needs to notify vaccine recipients or who will enforce the mandate, but the states health department has updated its vaccine information website to include details on how the single-shot vaccine was manufactured. Fact sheets from the health department also include such details.

The Johnson & Johnson COVID-19 vaccine has been produced by growing the virus in fetal cells during vaccine development and manufacturing (using the PER.C6.line). Even though fetal cells are used to grow the vaccine virus, vaccines do not contain these cells or pieces of DNA. The mRNA vaccines (those by Pfizer and Moderna) did not use a fetal cell line to produce or manufacture the vaccine, a frequently asked questions page from the Michigan Department of Health and Human Services states.

The move was lauded by anti-abortion groups while some Michigan Democrats criticized their Republican colleagues of politicizing the states public health effort to fight the coronavirus.

Colleagues, this pandemic was never supposed to be political. Wear a mask, wash your hands, do your best to keep distant from others really simple, basic instructions to help keep us safe and keep others safe, state Sen. Erika Geiss (D) said in opposition to the language in the bill.

Its disappointing but not surprising that youre putting politics into this process in order to scare people from getting this extremely safe vaccine.

Earlier this month, Michigans Catholic Bishops issued a statement calling the Johnson & Johnson vaccine and AstraZeneca vaccine, which has yet to receive emergency use authorization in the U.S., morally problematic. They urged Catholics to only take the vaccine if there were no other alternatives.

READ MORE STORIES FROM CHANGING AMERICA

FAUCI SAYS NEW SURGE IN COVID-19 CASES HAS THREE MAIN CAUSES

TRUMP WHITE HOUSE CENSORED HEAD OF ITS OWN CORONAVIRUS TASK FORCE, NEW REPORT SAYS

THIS IS NOW THE WORST US STATE FOR COVID-19 INFECTIONS

TRUMPS HEAD OF CORONAVIRUS TASK FORCE SAYS MOST COVID-19 DEATHS COULD HAVE BEEN PREVENTED

TRUMPS CDC DIRECTOR MAKES SHOCKING STATEMENT ABOUT ORIGIN OF COVID-19 IN WUHAN LAB

Original post:
New Michigan law requires those receiving Johnson & Johnson vaccine be told it was developed using stem cells | TheHill - The Hill

Human Embryonic Stem Cells (HESC) Market 2021 Is Rapidly Increasing Worldwide in Near Future | Top Companies Analysis- ESI BIO, Thermo Fisher,…

A detailed report entitled, Global Human Embryonic Stem Cells (HESC) Market recently published by DataIntelo offers a comprehensive outlook of the global Human Embryonic Stem Cells (HESC) market. It is an all-inclusive report that provides lucid and precise information about the crucial aspects of key components and players of the market. The report offers a robust assessment of the Human Embryonic Stem Cells (HESC) market to understand the scope of the growth potential, revenue growth, product range, and pricing factors besides analysis the market size, market performance, and market dynamics of the Human Embryonic Stem Cells (HESC) market. Moreover, the report is thoroughly assessed to draw a broader picture of the market by a detailed study of the current market trend and examines the potential expansion and growth of the Human Embryonic Stem Cells (HESC) market during the forecast period, 2020-2027.

Key companies that are covered in this report:

ESI BIO Thermo Fisher BioTime MilliporeSigma BD Biosciences Astellas Institute of Regenerative Medicine Asterias Biotherapeutics Cell Cure Neurosciences PerkinElmer Takara Bio Cellular Dynamics International Reliance Life Sciences Research & Diagnostics Systems SABiosciences STEMCELL Technologies Stemina Biomarker Discovery Takara Bio TATAA Biocenter UK Stem Cell Bank ViaCyte Vitrolife

*Note: Additional companies can be included on request

Get Free Exclusive PDF Sample Of This Report: https://dataintelo.com/request-sample/?reportId=94347

The report has an exclusive chapter on the COVID-19 pandemic and its major impact of the manufacturing of products and other services related to the market. It also makes a concrete assessment of the potential impact of the ongoing COVID-19 in the next coming years. With this information, the report aims to assist clients to formulate an effective market strategies and investment plan to make a change in their business outlook. Moreover, the report covers key strategies and plans adopted by some major players to ensure their market presence and to remain intact in the global competition.

This market report provides a holistic view about the market dynamics and overall outlook through providing a concrete explanation about key drivers, restrains, opportunities, and challenges in the coming years. It also offers key insight about the current market trend and performance in respect to various products associated with the market. It also highlights key insights on which component is expected to expand significantly and which region is emerging as the key potential destination of the Human Embryonic Stem Cells (HESC) market. Moreover, it provides a critical assessment of the emerging competitive landscape of the manufacturers as the demand for the Human Embryonic Stem Cells (HESC) is projected to increase substantially across the different regions.

The report, published by DataIntelo, is the most accurate and reliable information due to its wide research activities from a dedicated team. The report is prepared using a robust research methodology focusing on primary as well as secondary sources. The report is prepared by relying on primary source including interviews of the company executives & representatives and accessing official documents, websites, and press release of the companies. The DataIntelos report is widely known for its accuracy and factual figures as it consists of a concise graphical representations, tables, and figures which displays a clear picture of the developments of the products and its market performance over the last few years.

You can buy the complete report in PDF format @ https://dataintelo.com/checkout/?reportId=94347

You can also go for a yearly subscription of all the updates on Human Embryonic Stem Cells (HESC) market.

The report covers a detailed performance of some of the key players and analysis of major players in the industry, segments, application and regions. Moreover, the report also takes into account the governments policies in the evaluation of the market behavior to illustrate the potential opportunities and challenges of the market in each region. The report also covers the recent agreements including merger & acquisition, partnership or joint venture and latest developments of the manufacturers to sustain in the global competition of the Human Embryonic Stem Cells (HESC) market.

By Types:

Totipotent Stem Cells Pluripotent Stem Cells Unipotent Stem Cells

By Applications:

Research Clinical Trials Others

As per the estimation of DataIntelo, the global Human Embryonic Stem Cells (HESC) market was valued at UDS XX million and is projected to reach a value of USD XX million by the end of 2027, expanding at a CAGR of XX% through the forecast period. The report covers the performance of the Human Embryonic Stem Cells (HESC) in regions, North America, Latin America, Europe, Asia Pacific, and Middle East & Africa by focusing some key countries in the respective regions. As per the clients requirements, this report can be customized and available in a separate report for the specific region and countries.

The following is the TOC of the report:

Executive Summary

Assumptions and Acronyms Used

Research Methodology

Human Embryonic Stem Cells (HESC) Market Overview

Global Human Embryonic Stem Cells (HESC) Market Analysis and Forecast by Type

Global Human Embryonic Stem Cells (HESC) Market Analysis and Forecast by Application

Global Human Embryonic Stem Cells (HESC) Market Analysis and Forecast by Sales Channel

Global Human Embryonic Stem Cells (HESC) Market Analysis and Forecast by Region

North America Human Embryonic Stem Cells (HESC) Market Analysis and Forecast

Latin America Human Embryonic Stem Cells (HESC) Market Analysis and Forecast

Europe Human Embryonic Stem Cells (HESC) Market Analysis and Forecast

Asia Pacific Human Embryonic Stem Cells (HESC) Market Analysis and Forecast

Asia Pacific Human Embryonic Stem Cells (HESC) Market Size and Volume Forecast by Application

Middle East & Africa Human Embryonic Stem Cells (HESC) Market Analysis and Forecast

Competition Landscape

Customize Report and Inquiry for the Human Embryonic Stem Cells (HESC) market report @ https://dataintelo.com/enquiry-before-buying/?reportId=94347

Why you should buy this report?

This report offers a concise analysis of the Human Embryonic Stem Cells (HESC) market for the last 5 years with historical data & more accurate prediction for upcoming 6 years on the basis of statistical information. This report helps you to understand the market components by offering a cohesive framework of the key players and their competition dynamics as well as strategies. The report is a complete guideline for the clients to arrive an informed business decision since it consists of a detailed information for better understandings of the current & future market situation.

The report also answers some of the key questions given below:

About DataIntelo:

We keep our priority to fulfil the needs of our customers by offering authentic and inclusive reports for the global market-related domains. With a genuine effort from a dedicated team of business experts, DataIntelo has been in the service by providing innovative business ideas and strategies for the current global market for various industries and set its benchmark in the market research industry. We have a large support of database from various leading organizations and business executives across the globe; so, we excel at customized report as per the clients requirements and updating market research report on the daily basis with quality information.

Contact Info:

Name: Alex Mathews

Address: 500 East E Street, Ontario,

CA 91764, United States.

Phone No: USA: +1 909 545 6473

Email:[emailprotected]

Website:https://dataintelo.com

Read more here:
Human Embryonic Stem Cells (HESC) Market 2021 Is Rapidly Increasing Worldwide in Near Future | Top Companies Analysis- ESI BIO, Thermo Fisher,...

Global Human Embryonic Stem Cells Industry Market 2021 In-depth Industry Analysis, Growth By 2027:Lonza Group Ltd., Life Technologies Corporation,…

This elaborate research report on global Human Embryonic Stem Cells market, composed and compiled by Orbis Pharma Reports encompasses elaborate SWOT and PESTEL analysis derivatives to imbibe exact pulse of the market, which is integral for future ready investment decisions. The report is a highly dependable, unbiased reference documentation that lends ample clarity upon market growth structure, market size and dimensions as well as future-ready developments plans and market opportunities.

Get Sample Copy Of Report Here: https://www.orbispharmareports.com/sample-request/87361

The report also sums up overall developments across political, social, economical spheres that are pivotal growth influencers. Based on concrete understanding, future ready investment decisions are directed to encourage hefty returns. The report is an up-to-date representation of multi-faceted developments prevalent in global Human Embryonic Stem Cells market and effectively encompasses noteworthy trends, revenue returns, growth patterns as well as renders cues on market share, demand and supply derivatives that collectively inspire balanced growth and development.

Human Embryonic Stem Cells Market Top Manufactures Details Here:

Lonza Group Ltd. Life Technologies Corporation NuVasive Inc. TiGenix N.V Sumanas Aastrom Biosciences Cynata Therapeutics Ltd. Genlantis Anterogen Co., Ltd CellTherapies P/L BioRestorative Therapies Inc. Vericel Corporation BrainStorm Cell Therapeutics Inc. Cesca Therapeutics Inc. Kite Pharma Inc. PromoCell Orthofix International N.V. Ocata Therapeutics Inc. Beike Biotechnology

Browse the Complete Here: https://www.orbispharmareports.com/covid-19-outbreak-global-human-embryonic-stem-cells-industry-market-report-development-trends-threats-opportunities-and-competitive-landscape-in-2020/

The report by Orbis Pharma Reports on global Human Embryonic Stem Cells market encourages complete stratification of the market in terms of segments to understand growth patterns. All prominent segments highlighted in the report have been assessed based on set parameters such as capital diversion, inventory management as well as utility diversification, besides exploring supply chain developments to understand segment potential in growth progression. Each of the segment identified has been assessed on the basis of various market parameters to explore growth projections and likelihood. Specific references of vendor activities across growth hotspots, in alignment with end-user preferences and industry needs have been meticulously reflected in the report to understand growth specific capabilities of various dynamic segments.

Human Embryonic Stem Cells Market By the product type:

Adult Sources Fetal Sources Others

Human Embryonic Stem Cells Market By the application:

Hematopoietic stem cell transplantation Tissue repair damage Autoimmune diseases As gene therapy vectors.

What to Expect from the Report? * A systematic compilation of key-player assessment with significant detailing of potential threats and rampant market opportunities have been neatly addressed in this report by Orbis Pharma Reports. * A clear perspective of dominant market trends that influence balanced growth and revenue stability. * A thorough profiling of leading vendors with disparate details of potential growth strategies and planning

For Any Query on the Report: https://www.orbispharmareports.com/enquiry-before-buying/87361

About Us :

At Orbispharma we curate the most relevant news stories, features, analysis and research reports on the important challenges undertaken by the pharmaceutical and related sectors. Our editorial philosophy is to bring you sharp, focused and informed perspective of industries, the end users and application of all upcoming trends into the pharma sector. Orbispharma believes in conversations that can bring a change in one of the most crucial economic sectors in the world. With these conversations we wish our customers to make sound business decisions with right business intelligence.

Contact Us :

Original post:
Global Human Embryonic Stem Cells Industry Market 2021 In-depth Industry Analysis, Growth By 2027:Lonza Group Ltd., Life Technologies Corporation,...

Xenobots 2.0 are Here and Still Developed With Frog Stem Cells – Unite.AI

The same team of biologists and computer scientists from Tufts University and the University of Vermont that created the Xenobots last year have now developed Xenobots 2.0. Last years version were novel, tiny self-healing biological machines created from frog cells, and they could navigate, push payloads, and act as a collective unit in some cases.

The new Xenobots 2.0 are life forms that can self-assemble a body from single cells. They do not require muscles to move, and they have even demonstrated recordable memory. Compared to their previous counterparts, the new bots move faster, navigate even more environments, and have longer lifespans. At the same time, they can still work together and heal themselves when damaged.

The new research was published in Science Robotics.

With the Xenobots 1.0, the millimeter-sized automations were constructed top down, with the manual placement of tissue and surgical shaping of frog skin and cardiac cells, which produces motion. With the new version of the technology, they were constructed bottom up.

Stem cells were taken from the embryos of the African frog called Xenopus laevis, and this enabled them to self-assemble and grow into spheroids. After a few days, the cells differentiated and produced cilia that moved back and forth or rotated in a specific way.

These cilia provide the new bots with a type of legs that enables them to rapidly travel across surfaces. In the biological world, cilia, or tiny hair-like projections, are often found on mucous surfaces like the lungs. They help by pushing out foreign material and pathogens, but in the Xenobots, they offer rapid locomotion.

Michael Levin is a Distinguished Professor of Biology and director of the Allen Discovery Center at Tufts University. He is the corresponding author of the study.

We are witnessing the remarkable plasticity of cellular collectives, which build a rudimentary new body that is quite distinct from their default in this case, a frog despite having a completely normal genome, said Levin. In a frog embryo, cells cooperate to create a tadpole. Here, removed from that context, we see that cells can re-purpose their genetically encoded hardware, like cilia, for new functions such as locomotion. It is amazing that cells can spontaneously take on new roles and create new body plans and behaviors without long periods of evolutionary selection for those features.

Senior scientist Doug Blackiston was co-first author of the study along with research technician Emma Lederer.

In a way, the Xenobots are constructed much like a traditional robot. Only we use cells and tissues rather than artificial components to build the shape and create predictable behavior. said Blackiston On the biology end, this approach is helping us understand how cells communicate as they interact with one another during development, and how we might better control those interactions.

Over at UVM, the scientists were developing computer simulations that modeled different shapes of the Xenobots, which helped identify any different behaviors that were exhibited in both individuals and groups. The team relied on the Deep Green supercomputer cluster at UVMs Vermont Advanced Computing Core.

Led by computer scientists and robotics expert Josh Bongard, the team came up with hundreds of thousands of environmental conditions through the use of an evolutionary algorithm. The simulations were then used to identify Xenobots that could work together in swarms to gather debris in a field of particles.

We know the task, but its not at all obvious for people what a successful design should look like. Thats where the supercomputer comes in and searches over the space of all possible Xenobot swarms to find the swarm that does the job best, says Bongard. We want Xenobots to do useful work. Right now were giving them simple tasks, but ultimately were aiming for a new kind of living tool that could, for example, clean up microplastics in the ocean or contaminants in soil.

The new version of the bots are faster and more efficient at tasks like garbage collection, and they can now cover large flat surfaces. The new upgrade also includes the ability for the Xenobot to record information.

The most impressive new feature of the technology is the ability for the bots to record memory, which can then be used to modify its actions and behaviors. The newly developed memory function was tested and the proof of concept demonstrated that it could be extended in the future to detect and record light, the presence of radioactive contamination, chemical pollutants, and more.

When we bring in more capabilities to the bots, we can use the computer simulations to design them with more complex behaviors and the ability to carry out more elaborate tasks, said Bongard. We could potentially design them not only to report conditions in their environment but also to modify and repair conditions in their environment.

The new version of the robots are also able to self-heal very efficiently, demonstrating that they are capable of closing the majority of a severe full-length laceration half their thickness within just five minutes.

The new Xenobots carry over the ability to survive up to ten days on embryonic energy stores, and their tasks can be carried out with no additional energy sources. If they are kept in various different nutrients, they can continue at full speed for months.

View post:
Xenobots 2.0 are Here and Still Developed With Frog Stem Cells - Unite.AI

AgeX Therapeutics Reports Fourth Quarter and Annual 2020 Financial Results and Provides Business Update – Business Wire

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (AgeX; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the fourth quarter and the full year ended December 31, 2020.

Recent Highlights

Liquidity and Capital Resources

Amendment to 2019 Loan Agreement

On February 10, 2021, AgeX entered into an amendment to its 2019 Loan Facility Agreement with Juvenescence Limited (Juvenescence). The Amendment extends the maturity date of loans under the agreement to February 14, 2022 and increases the amount of the loan facility by $4.0 million. All loans in excess of the initial $2.0 million that AgeX previously borrowed are subject to Juvenescences discretion.

At-the-market Offering Facility

During January 2021 AgeX entered into a sales agreement with Chardan Capital Markets LLC (Chardan) for the sale of shares of AgeX common stock in at-the-market (ATM) transactions. In accordance with the terms of the sales agreement, AgeX may offer and sell shares of common stock having an aggregate offering price of up to $12.6 million through Chardan acting as the sales agent. Through March 26, 2021, AgeX raised approximately $496,000 in gross proceeds through the sale of shares of common stock.

Going Concern Considerations

As required under Accounting Standards Update 2014-15, Presentation of Financial Statements-Going Concern (ASC 205-40), AgeX evaluates whether conditions and/or events raise substantial doubt about its ability to meet its future financial obligations as they become due within one year after the date its financial statements are issued. Based on AgeXs most recent projected cash flows, AgeX believes that its cash and cash equivalents and available sources of debt and equity capital would not be sufficient to satisfy AgeXs anticipated operating and other funding requirements for the twelve months following the filing of AgeXs Annual Report on Form 10-K for the year ended December 31, 2020. These factors raise substantial doubt regarding the ability of AgeX to continue as a going concern.

Balance Sheet Information

Cash, and cash equivalents, and restricted cash totaled $0.6 million as of December 31, 2020, as compared with $2.5 million as of December 31, 2019. Since January 1, 2021, AgeX had cash proceeds of approximately $3.2 million through loans from Juvenescence, sales of shares of AgeX common stock, and the disposition of its subsidiary LifeMap Sciences, Inc. (LifeMap Sciences) through a cash-out merger.

Fourth Quarter and Annual 2020 Operating Results

Revenues: Total Revenues for the fourth quarter of 2020 were $0.5 million. Total revenues for the year ended December 31, 2020 were $1.9 million, as compared with $1.7 million in the same period in 2019. AgeX revenue was primarily generated by its subsidiary LifeMap Sciences, Inc. which AgeX disposed of on March 15, 2021 through a cash-out merger. Revenues for the year ended December 31, 2020 also included approximately $0.3 million of allowable expenses under a research grant from the NIH as compared with $0.2 million in the same period in 2019.

Operating expenses: Operating expenses for the three months ended December 31, 2020, were $2.9 million, as reported, which was comprised of $2.5 million for AgeX and $0.4 million for LifeMap Sciences, and were $2.3 million, as adjusted, comprised of $2.0 million for AgeX and $0.3 million for LifeMap Sciences.

Operating expenses for the full year 2020 were $12.4 million, as reported, which was comprised of $10.4 million for AgeX and $2.0 million for LifeMap Sciences, and were $10.2 million, as adjusted, comprised of $8.7 million for AgeX and $1.5 million for LifeMap Sciences.

Research and development expenses for the year ended December 31, 2020 decreased by $0.9 million to $5.0 million from $5.9 million in 2019. The decrease was primarily attributable to the layoff of research and development personnel in May 2020.

General and administrative expenses for the year ended December 31, 2020 decreased by $0.7 million to $7.4 million from $8.1 million in 2019. Increases in personnel costs related to an increase in administrative staffing were offset to some extent by a decrease in noncash stock-based compensation expense, general office expense and supplies and travel related expenses with the shelter in place mandates since March 15, 2020 resulting from the COVID-19 pandemic, and the elimination of shared facilities and services fees from AgeXs former parent Lineage Cell Therapeutics, Inc. following the termination of a Shared Facilities and Services Agreement on September 30, 2019.

The reconciliation between operating expenses determined in accordance with accounting principles generally accepted in the United States (GAAP) and operating expenses, as adjusted, a non-GAAP measure, is provided in the financial tables included at the end of this press release.

Other expense, net: Net other expense for the year ended December 31, 2020 was $0.5 million, as compared with net other income of $0.3 million in the same period in 2019. The change is primarily attributable to increased amortization of deferred debt costs to interest expense following the consummation of loan agreements.

Net loss attributable to AgeX: The net loss attributable to AgeX for the year ended December 31, 2020 was $10.9 million, or ($0.29) per share (basic and diluted) compared to $12.2 million, or ($0.33) per share (basic and diluted), for the same period in 2019.

About AgeX Therapeutics

AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics to treat human diseases to increase healthspan and combat the effects of aging. AgeXs PureStem and UniverCyte manufacturing and immunotolerance technologies are designed to work together to generate highly defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeXs revolutionary longevity platform induced Tissue Regeneration (iTR) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. HyStem is AgeXs delivery technology to stably engraft PureStem or other cell therapies in the body. AgeX is seeking opportunities to establish licensing and collaboration arrangements around its broad IP estate and proprietary technology platforms and therapy product candidates.

For more information, please visit http://www.agexinc.com or connect with the company on Twitter, LinkedIn, Facebook, and YouTube.

Forward-Looking Statements

Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as will, believes, plans, anticipates, expects, estimates should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in the Risk Factors section of AgeXs most recent Annual Report on Form 10-K filed with the Securities and Exchange Commissions (copies of which may be obtained at http://www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

AGEX THERAPEUTICS, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(In thousands, except par value amounts)

December 31,

2020

2019

ASSETS

CURRENT ASSETS

Cash and cash equivalents

$

527

$

2,352

Accounts and grants receivable, net

326

363

Prepaid expenses and other current assets

1,430

1,339

Total current assets

2,283

4,054

Link:
AgeX Therapeutics Reports Fourth Quarter and Annual 2020 Financial Results and Provides Business Update - Business Wire

OSE Immunotherapeutics Receives Authorization for Phase 1 Clinical Trial of its Multi-Target Multi-Variant COVID-19 Vaccine

NANTES, France, April 01, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today announced that the Belgian Federal Agency for Medicines and Health Products (Agence Fédérale des Médicaments et des Produits de Santé - AFMPS) and the Belgian Ethics Committee approved the Phase 1 trial evaluating its COVID-19 vaccine, named CoVepiT, on 48 healthy volunteers. First subjects are expected to be enrolled shortly.

Continue reading here:
OSE Immunotherapeutics Receives Authorization for Phase 1 Clinical Trial of its Multi-Target Multi-Variant COVID-19 Vaccine

AgraFlora Announces Definitive Agreement to Sell its AAA Heidelberg Subsidiary

VANCOUVER, British Columbia, April 01, 2021 (GLOBE NEWSWIRE) -- AgraFlora Organics International Inc. (“AgraFlora” or the “Company”) (CSE: AGRA) (Frankfurt: PU31) (OTCPK: AGFAF) is pleased to announce the signing of a definitive agreement (the “Agreement”) to sell its wholly-owned subsidiary, AAA Heidelberg Inc. (“AAA”), for cash consideration of approximately $1 million (the “Transaction”). AAA operates an 8,800 square foot indoor growing facility in London, Ontario. The closing of the Transaction is subject to customary approvals and is expected to occur in the second quarter of 2021.

Original post:
AgraFlora Announces Definitive Agreement to Sell its AAA Heidelberg Subsidiary